DUBLIN, Ohio, and WAUWATOSA, Wis., March 18 /PRNewswire-FirstCall/ --
Cardinal Health and GE Healthcare announced an agreement today to broaden
the availability of GE Healthcare's Myoview(TM) (Tetrofosmin) cardiac
imaging agent through Cardinal Health's leading network of specialized
nuclear pharmacies.
The agreement will give Cardinal Health's customers greater access to
Myoview(TM), a leading myocardial perfusion imaging technetium agent used
in the diagnosis and treatment of heart disease.
"With this agreement, Myoview will over time become the flagship
branded cardiac imaging agent offered through Cardinal Health's nuclear
pharmacies," said John Rademacher, president, Nuclear and Specialty
Pharmacy Services for Cardinal Health. "Our commitment to the nuclear
pharmacy business runs deep, and partnering with GE Healthcare to provide
broader access to their product portfolio illustrates the unique way
Cardinal Health can bring service and value to our customers and the
nuclear medicine community."
Cardinal Health operates the largest radiopharmacy network in the
United States with more than 150 nuclear pharmacy locations. It is also the
largest employer of nuclear pharmacists in the world. The combination of
that expertise and the size of its network allows Cardinal Health to reach
85 percent of all U.S. hospitals within three hours and provide service and
clinical expertise to the nuclear medicine community.
"GE Healthcare and Cardinal Health are ideal collaborators to advance
the field of nuclear medicine," said John Chiminski, president and CEO of
Medical Diagnostics at GE Healthcare. "Myoview has been a strong and
growing brand in the nuclear cardiac imaging market for more than a decade,
and partnering to bring it to Cardinal Health's radiopharmacies will help
clinicians reach even more patients."
"We are committed to continually investing in nuclear medicine," said
Chiminski. "We believe working together with Cardinal Health will help us
to do just that."
ABOUT CARDINAL HEALTH
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an
$87 billion, global company serving the health care industry with products
and services that help hospitals, physician offices and pharmacies reduce
costs, improve safety, productivity and profitability, and deliver better
care to patients. With a focus on making supply chains more efficient,
reducing health care-associated infections and breaking the cycle of
harmful medication errors, Cardinal Health develops market-leading
technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing
systems, MedMined(TM) electronic infection surveillance service, VIASYS(R)
respiratory care products and the CareFusion(TM) patient identification
system. The company also manufactures medical and surgical products and is
one of the largest distributors of pharmaceuticals and medical supplies
worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more
than 40,000 people on five continents. More information about the company
may be found at http://www.cardinalhealth.com
ABOUT GE HEALTHCARE
GE Healthcare provides transformational medical technologies and
services that are shaping a new age of patient care. Our expertise in
medical imaging and information technologies, medical diagnostics, patient
monitoring systems, performance improvement, drug discovery, and
biopharmaceutical manufacturing technologies is helping clinicians around
the world re-imagine new ways to predict, diagnose, inform, treat and
monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare
providers to better diagnose and treat cancer, heart disease, neurological
diseases and other conditions earlier. Our vision for the future is to
enable a new "early health" model of care focused on earlier diagnosis,
pre-symptomatic disease detection and disease prevention. Headquartered in
the United Kingdom, GE Healthcare is a $17 billion unit of General Electric
Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000
people committed to serving healthcare professionals and their patients in
more than 100 countries. For more information about GE Healthcare, visit
our website at http://www.gehealthcare.com.
ABOUT MYOVIEW, SELECT SAFETY INFORMATION
Myoview(TM) (technetium Tc-99m Tetrofosmin) In studying patients with
known or suspected coronary artery disease, care should be taken to ensure
continuous cardiac monitoring and the availability of emergency cardiac
treatment. As with all injectable drug products, allergic reactions and
anaphylaxis may occur. Pharmacologic induction of cardiovascular stress may
be associated with serious adverse events such as myocardial infarction,
arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events.
Caution should be used when pharmacologic stress is selected as an
alternative to exercise; it should be used when indicated and in accordance
with the pharmacologic stress agent's labeling. The most common adverse
reactions reported from post-marketing experience with Myoview included
rash, urticaria, abnormal vision, allergic reactions, and fever.
Before use of the product please refer to the product's full
prescribing information, available at http://www.myoview.com/
SOURCE GE Healthcare; Cardinal Health
 back to top
Related links:
http://www.cardinalhealth.com
http://www.gehealthcare.com http://www.myoview.com
CONTACT:
For GE Healthcare, Wauwatosa, Media, Ryan
Fitzgerald, +1-414-530-2735, ryan.fitzgerald@ge.com; or for
Cardinal Health, Media, Troy Kirkpatrick, +1-614-757-6225,
troy.kirkpatrick@cardinalhealth.com, or Investors, Jon Lyons,
+1-614-757-3996, jon.lyons@cardinalhealth.com
|
